ACHL

Achilles Therapeutics

1.00 USD
+0.01
0.81%
Updated Oct 22, 10:36 AM EDT
1 day
0.81%
5 days
4.99%
1 month
2.50%
3 months
21.95%
6 months
26.58%
Year to date
14.68%
1 year
12.36%
5 years
-93.96%
 

About: Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Employees: 215

0
Funds holding %
of 6,740 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

3.47% less ownership

Funds ownership: 57.47% [Q1] → 54.0% (-3.47%) [Q2]

16% less funds holding

Funds holding: 32 [Q1] → 27 (-5) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

39% less capital invested

Capital invested by funds: $29.4M [Q1] → $18.1M (-$11.3M) [Q2]

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Research analyst outlook

We haven’t received any recent analyst ratings for ACHL.

Financial journalist opinion

Charts implemented using Lightweight Charts™